Multicentric double blinded randomized controlled trial in 100 centers from China, Australia, India, Canada, and Malaysia in which 0.6 to 0.8 mg/kg/d of oral methylprednisolone for 2 months, with a slow taper over 4 to 6 months was intended to be studied against placebo in 262 participants with IgAN with >1 g/day proteinuria & eGFR between 20 and 120 after a 3 month optimal blood pressure control with renin angiotensin blockade. Primary outcome was a composite of 40% decrease in eGFR, the development of ESRD (defined as a need for maintenance dialysis or kidney transplantation), or death due to kidney disease. The hazard ratio for the primary outcome was 0.37 (0.17-0.85) favoring steroids. The study had to be terminated owing to an excess of SAEs (mostly infections) in the corticosteroid group
